Compare · HYPR vs LIVN
HYPR vs LIVN
Side-by-side comparison of Hyperfine Inc. (HYPR) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HYPR and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.32B, about 52.3x HYPR ($82.7M).
- HYPR has been more active in the news (4 items in the past 4 weeks vs 2 for LIVN).
- LIVN has more recent analyst coverage (21 ratings vs 4 for HYPR).
- Company
- Hyperfine Inc.
- LivaNova PLC
- Price
- -
- -
- Market cap
- $82.7M
- $4.32B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 4
- 2
- Recent ratings
- 4
- 21
Hyperfine Inc.
Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest HYPR
- SEC Form 8-K filed by Hyperfine Inc.
- Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026
- Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million
- Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets
- Hyperfine Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents
- Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference
- Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans
- Chief Operating Officer Teisseyre Thomas sold $6,273 worth of shares (7,345 units at $0.85), decreasing direct ownership by 1% to 671,256 units (SEC Form 4) to cover withholding tax
- CFO and CAO Hale Brett sold $6,273 worth of shares (7,345 units at $0.85), decreasing direct ownership by 1% to 592,420 units (SEC Form 4) (tax withholding)
Latest LIVN
- Barclays initiated coverage on LivaNova with a new price target
- LivaNova to Announce Third-Quarter 2026 Results
- SEC Form 4 filed by Chief Legal Officer Liddy Anne M.
- Director Bianchi Francesco sold $273,032 worth of Ordinary Shares (3,500 units at $78.01), decreasing direct ownership by 44% to 4,434 units (SEC Form 4)
- Director Story Brooke sold $187,270 worth of Ordinary Shares (2,300 units at $81.42), decreasing direct ownership by 23% to 7,488 units (SEC Form 4)
- LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
- Director Bianchi Francesco sold $131,538 worth of Ordinary Shares (1,650 units at $79.72), decreasing direct ownership by 17% to 7,934 units (SEC Form 4)
- SEC Form 3 filed by new insider Liddy Anne M.
- Chief Innovation Officer Tezel Ahmet exercised 12,692 units of Ordinary Shares at a strike of $52.68, returned $668,740 worth of Ordinary Shares to the company (8,589 units at $77.86), covered exercise/tax liability with 1,428 units of Ordinary Shares and sold $207,942 worth of Ordinary Shares (2,675 units at $77.74) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by LivaNova PLC